In a clinical trial that followed, Dranoff and colleagues strengthened their murine findings in patients with metastatic melanomas by showing that GM-CSF-secreting melanoma cell-based vaccines improve clinical outcomes and mediate tumor shrinkage by activating cytotoxic T cell-mediated immune responses (102). The gene discussed is CSF2; the disease is melanoma.